Gutiérrez MA, Pardo AB, Gámez MR, Mas FR, García CH, Goicochea CE

Idioma: Español
Referencias bibliográficas: 29
Paginas:
Archivo PDF: 361.29 Kb.

RESUMEN

Introducción: el finasteride, inhibidor específico de la 5 α-reductasa prostática, se utiliza en el tratamiento de la hiperplasia prostática benigna. Ha sido descrito que su exposición prenatal inhibe el desarrollo mediado por dihidrotestosterona y produce cambios altamente predictivos de malformaciones del tracto reproductivo de la rata macho.
Objetivo: confirmar los efectos que produce el finasteride cuando se administra a ratas preñadas en el período de diferenciación sexual en condiciones de laboratorio del Centro de Productos Naturales, con vistas a utilizarlo como control positivo del daño sobre el proceso de reproducción.
Métodos: se administró finasteride 10 mg/kg/día por vía oral del día 12 al 21 de la gestación a las ratas Sprague Dawley preñadas.
Resultados: el grupo tratado con finasteride mostró diferencias significativas en relación con el control en cuanto al descenso de testículos. La separación prepucial de las crías estuvo retrasada por el finasteride a los días 40 y 45 posnacimiento, y todas las crías machos presentaron rasgos feminizados como retención de tetillas (100 %), hendidura prepucial (83,9 %) y reducción de la distancia anogenital (90,3 %), siendo significativamente mayor que en los controles. Además, 2 animales presentaron testículos ectópicos (6,5 %), lo que difirió significativamente del control. Los machos expuestos al finasteride in utero mostraron atrofia de estructuras genitales, con reducción significativa del peso relativo de órganos sexuales accesorios con respecto al control.
Conclusiones: estos resultados, coherentes con la literatura, indican que el finasteride indujo alteraciones sobre la respuesta andrógeno-dependiente luego de la exposición in utero y confirman la validez de su uso, en nuestras condiciones, como control positivo en estudios de reproducción.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Berman DM, Tian H, Russell DW. Expression and regulation of steroid 5 -reductase in the urogenital tract of the fetal rat. Mol Endocrinol. 1995;9:1561-70.

2. Clark RL, Anderson CA, Prahalada S, Robertson RT, Lochry EA, Leonard YM, et al. Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5 alpha-reductase inhibitor. Toxicol Appl Pharmacol. 1993;119(1):34-40.

3. Imperato-McGinley J, Binienda Z, Arthur A, Mininberg DT, Vaughan ED, Quimby FW. The development of a male pseudohermaphroditic rat using an inhibitor of the enzyme 5 -reductase. Endocrinology. 1985;116:807-12.

4. Veyssiere G, Berger M, Jean-Faucher C, Turckheim M de, Jean C. Testosterone and dihydrotestosterone in sexual ducts and genital tubercle of rabbit fetuses during sexual organogenesis: effects of fetal decapitation. J Steroid Biochem. 1982;17:149-54.

5. Wilson JD, Lasnitzki I. Dihydrotestosterone formation in fetal tissues of the rabbit and rat. Endocrinology. 1971;89:659-68.

6. Imperato-McGinley J, Binienda Z, Gedney J, Vaughan ED. Nipple differentiation in fetal male rats treated with an inhibitor of the enzyme 5 -reductase: definition of a selective role for dihydrotestosterone. Endocrinology. 1986;118:132-7.

7. Kratochwil K. Development and loss of androgen responsiveness in the embryonic rudiment of the mouse mammary gland. Dev Biol. 1977;61:358-65.

8. Gormley GJ, Stoner E, Bruskewitz RC. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185-91.

9. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 -reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74:505-8.

10. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996;48:398-405.

11. Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003;74(2):393-406.

12. Hib J, Ponzio R. The abnormal development of male sex organs in the rat using a pure antiandrogen and a 5 alpha-reductase inhibitor during gestation. Acta Physiol Pharmacol Ther Latinoam. 1995;45(1):27-33.

13. Imperato-McGinley J, Sanchez RS, Spencer JR, Yee B, Vaughan ED. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies. Endocrinology. 1992;131(3):1149-56.

14. Anderson CA, Clark RL. External genitalia of the rat: normal development and the histogenesis of 5 alpha-reductase inhibitor-induced abnormalities. Teratology. 1990;42(5):483-96.

15. Clark RL, Antonello JM, Grossman SJ, Wise LD, Anderson C, Bagdon WJ, et al. External genitalia abnormalities in male rats exposed in utero to finasteride, a 5 alphareductase inhibitor. Teratology. 1990;42(1):91-100.

16. Kolasa A, Marchlewicz M, Wenda-Rozewicka L, Wiszniewska B. Morphology of the testis and the epididymis in rats with dihydrotestosterone(DHT) deficiency. Rocz Akad Med Bialymst. 2004;49(Suppl 1):117-9.

17. Cukierski MA, Sina JL, Prahalada S, Wise LD, Antonello JM, Mc Donald JS, et al. Decreased fertility in male rats administered the 5 alpha-reductase inhibitor, finasteride, is due to deficits in copulatory plug formation. Reprod Toxicol. 1991;5(4):353-62.

18. Wise LD, Minsker DH, Cukierski MA, Clark RL, Prahalada S, Antonello JM, et al. Reversible decreases of fertility in male Sprague-Dawley rats treated orally with finasteride, a 5 alpha-reductase inhibitor. Reprod Toxicol. 1991;5(4):337-46.

19. George FW, Johnson L, Wilson JD. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat. Endocrinology. 1989;125(5):2434-8.

20. Mc Connell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-98.

21. Salewski E. Färbemethode zum makroskopischen Nachwweis von Implantationsstellen am Uterus der Ratte. Naunyn-Schmiedebewrgs. Arch Exp Pathol Pharmakol. 1964;247:367.

22. Austisier C. Behavioural reproductive toxicology: Regulatory requirements, technical problems, data interpretation. What attitude to adopt? In: Assandri A, Bussi R, Fumero S, editors. Topics in Reproductive Toxicology RB Meetings 2. Ivrea: RBM; 1987. p. 282-8.

23. Barlow NJ, McIntyre BS, Foster PMD. Permanent alteration of anogenital distance and nipple retention in male rats exposed to di(n-butyl) phthalate in utero. Toxicol Sci. 2002;66:233.

24. McIntyre BS, Barlow NJ, Foster PMD. Androgen mediated development in male rat offspring exposed to flutamide in utero: permanence and correlation of early postnatal changes in anogenital distance and nipple retention with malformations in androgendependent tissues. Toxicol Sci. 2001;62:236-49.

25. McIntyre BS, Barlow NJ, Foster PMD. Male rats exposed to linuron in utero exhibit permanent changes in anogenital distance, nipple retention, and epididymal malformations that result in subsequent testicular atrophy. Toxicol Sci. 2002;65:62- 70.

26. Gray LE, Ostby J, Monosson E, Kelce WR. Environmental antiandrogens: Low doses of the fungicide vinclozolin alter sexual differentiation of the male rat. Toxicol Ind Health. 1999;15:48-64.

27. George FW, Peterson KG. 5 -Dihydrotestosterone formation is necessary for embryogenesis of the rat prostate. Endocrinology. 1988;122:1159-64.

28. Blohm TR, Laughlin ME, Benson HD. Pharmacological induction of 5 -reductase deficiency in the rat: Separation of testosterone-mediated and 5 - dihydrotestosterone-mediated effects. Endocrinology. 1986;119:959-66.

29. Ostby J, Kelce WR, Lambright C, Wolf CJ, Mann P, Gray LE . The fungicide procymidone alters sexual differentiation in the male rat by acting as an androgenreceptor antagonist in vivo and in vitro. Toxicol Ind Health. 1999; 15:80-93.